Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival

Bone Marrow Transplant. 2019 Sep;54(9):1518-1520. doi: 10.1038/s41409-019-0493-5. Epub 2019 Feb 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allografts
  • Disease-Free Survival
  • Humans
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / mortality
  • Leukemia, Myeloid, Acute* / therapy
  • Maintenance Chemotherapy*
  • Male
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Sorafenib / administration & dosage*
  • Survival Rate
  • fms-Like Tyrosine Kinase 3 / genetics*

Substances

  • Sorafenib
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3